News articles about Onconova Therapeutics (NASDAQ:ONTX) have trended positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Onconova Therapeutics earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.7353308351108 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 (finance.yahoo.com)
- Onconova Therapeutics’ (ONTX) CEO Ramesh Kumar on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Onconova Therapeutics, Inc. (ONTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS (americanbankingnews.com)
- Keep Your Active Eyes on Onconova Therapeutics, Inc. (ONTX) with Unusual Volume Alert – Wall Street Morning (wallstreetmorning.com)
- Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results – Markets Insider (markets.businessinsider.com)
Onconova Therapeutics (ONTX) opened at $1.58 on Wednesday. Onconova Therapeutics has a 1-year low of $1.46 and a 1-year high of $3.88.
Onconova Therapeutics (NASDAQ:ONTX) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. sell-side analysts anticipate that Onconova Therapeutics will post -3.06 earnings per share for the current year.
ONTX has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Onconova Therapeutics in a report on Monday, October 9th. They issued a “buy” rating and a $6.00 price target on the stock. Dawson James restated a “buy” rating on shares of Onconova Therapeutics in a report on Tuesday, July 25th. ValuEngine upgraded shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Maxim Group set a $6.00 target price on shares of Onconova Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.33.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.